Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: A focus on depression

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1498-1505

  Szafran, Kinga ^a   Faron Górecka, Agata ^a   Kolasa, Magdalena ^a   Kuoemider, Maciej ^a   Solich, Joanna ^a   Zurawek, Dariusz ^a   Dziedzicka Wasylewska, Marta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Depression; G protein coupled receptors; Heterodimerization; Neuropsychiatric disorders

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GALANIN; HETERODIMER; MONOCLONAL ANTIBODY; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; SOMATOSTATIN RECEPTOR; VASOPRESSIN V1B RECEPTOR;

ANALYTIC METHOD; ANTIBODY LABELING; DEPRESSION; DIMERIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IN VITRO STUDY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROXIMITY LIGATION ASSAY; RECEPTOR BINDING ASSAY; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIMERIZATION; HUMANS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84894162570     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71510-X     Document Type: Article

References (27)

1. Cottet M, Albizu L, Comps-Agrar L, Trinquet E, Pin JP, Mouillac B, Durroux T: Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization. Methods Mol Biol, 2011, 746, 373-387.
2. Dulcis D, Jamshidi P, Leutgeb S, Spitzer NC: Neurotransmitter switching in the adult brain regulates behavior. Science, 2013, 340, 449-453.
3. Dziedzicka-Wasylewska M, Rogoz R, Klimek V, Maj J: Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J Neural Transm, 1997, 104, 515-524. (Pubitemid 27379906)
4. Engin E, Stellbrink J, Treit D, Dickson CT: Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience, 2008, 157, 666-676.
5. Fuxe K, Marcellino D, Genedani S, Agnati L: Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease. Mov Disord, 2007, 22, 1990-2017.
6. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M et al.: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97. (Pubitemid 351355090)
7. Gupta A, Heimann AS, Gomes I, Devi LA: Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen, 2008, 11, 463-467. (Pubitemid 351969362)
8. Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ et al.: GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2. Nature, 1998, 396, 674-679. (Pubitemid 29003945)
9. Jordan BA, Devi LA: G-protein-coupled receptor heterodimerization modulates receptor function. Nature, 1999, 399, 697-700. (Pubitemid 29289066)
10. Kuteeva E, Hökfelt T, Wardi T, Ogren SO: Galanin, galanin receptor subtypes and depression-like behaviour. Cell Mol Life Sci, 2008, 65, 1854-1863.
11. Lee SP, So CH, Rashid AJ, Varghese G, Cheng R, Lança AJ, O'Dowd BF, George SR: Dopamine D1 and D2 receptor co-activation generates a novel phospholipase Cmediated calcium signal. J Biol Chem, 2004, 279, 35671-35678. (Pubitemid 39100570)
12. Marullo S, Bouvier M: Resonance energy transfer approaches in molecular pharmacology and beyond. Trends Pharmacol Sci, 2007, 28, 362-365. (Pubitemid 47087970)
13. McGinty J, Stuckey DW, Soloviev VY, Laine R, Wylezinska-Arridge M, Wells DJ, Arridge SR et al.: In vivo fluorescence lifetime tomography of a FRET probe expressed in mouse. Biomed Opt Express, 2011, 2, 1907-1917.
14. Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T: CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol Psychiatry, 1991, 29, 1110-1118.
15. Nilsson A, Stroth N, Zhang X, Qi H, Falth M, Sköld K, Hoyer D: Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology, 2012, 62, 347-357.
16. Pallis E, Thermos K, Spyraki C: Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens. Eur J Neurosci, 2001, 14, 763-767. (Pubitemid 34626003)
17. Pallis E, Vasilaki A, Fehlmann D, Kastellakis A, Hoyer D, Spyraki C, Thermos K: Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology, 2009, 34, 952-963.
18. Pei L, Li S, Wang M, Diwan M, Anisman H, Fletcher PJ, Nobrega JN, Liu F: Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med, 2010, 16, 1393-1395.
19. Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ, Seeman P et al.: The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem, 2010, 285, 36625-36634.
20. Pfeiffer M, Koch T, Schröder H, Klutzny M, Kirscht S, Kreienkamp HJ, Höllt V, Schulz S: Homo-and heterodimerization of somatostatin receptor subtypes. Inactivation of sst3 receptor function by heterodimerization with sst2A. J Biol Chem, 2001, 276, 14027-14036.
21. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ et al.: International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev, 2007, 59, 5-13. (Pubitemid 46335687)
22. Renner U, Zeug A, Woehler A, Niebert M, Dityatev A, Dityateva G, Gorinski N et al.: Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking. J Cell Sci, 2012, 125, 2486-2499.
23. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157. (Pubitemid 30203051)
24. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC: Subtypes of the somatostatin receptor assemble as functional homo-and heterodimers. J Biol Chem, 2000, 275, 7862-7869. (Pubitemid 30159693)
25. Szafran K, £ukasiewicz S, Faron-Górecka A, Kolasa M, Kuoemider M, Solich J, Dziedzicka-Wasylewska M: Antidepressant drugs promote the heterodimerization of the dopamine D2 and somatostatin Sst5 receptorsfluorescence in vitro studies. Pharmacol Rep, 2012, 64, 1253-1258.
26. Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, Kamali-Moghaddam M, Söderberg O: Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics, 2010, 7, 401-409.
27. Young SF, Griffante C, Aguilera G: Dimerization between vasopressin V1b and corticotropin releasing hormone type 1 receptors. Cell Mol Neurobiol, 2007, 27, 439-461. (Pubitemid 46763890)